Now showing items 442-461 of 687

    • Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. 

      Garcia-Murillas, I; Schiavon, G; Weigelt, B; Ng, C; Hrebien, S; Cutts, RJ; Cheang, M; Osin, P; Nerurkar, A; Kozarewa, I; Garrido, JA; Dowsett, M; Reis-Filho, JS; Smith, IE; Turner, NC (2015-08)
      The identification of early-stage breast cancer patients at high risk of relapse would allow tailoring of adjuvant therapy approaches. We assessed whether analysis of circulating tumor DNA (ctDNA) in plasma can be used to ...
    • Mutational processes contributing to the development of multiple myeloma. 

      Hoang, PH; Cornish, AJ; Dobbins, SE; Kaiser, M; Houlston, RS (2019-08-06)
      To gain insight into multiple myeloma (MM) tumorigenesis, we analyzed the mutational signatures in 874 whole-exome and 850 whole-genome data from the CoMMpass Study. We identified that coding and non-coding regions are ...
    • Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma. 

      Qin, EY; Cooper, DD; Abbott, KL; Lennon, J; Nagaraja, S; Mackay, A; Jones, C; Vogel, H; Jackson, PK; Monje, M (2017-08-17)
      The lateral ventricle subventricular zone (SVZ) is a frequent and consequential site of pediatric and adult glioma spread, but the cellular and molecular mechanisms mediating this are poorly understood. We demonstrate that ...
    • Neutral tumor evolution in myeloma is associated with poor prognosis. 

      Johnson, DC; Lenive, O; Mitchell, J; Jackson, G; Owen, R; Drayson, M; Cook, G; Jones, JR; Pawlyn, C; Davies, FE; Walker, BA; Wardell, C; Gregory, WM; Cairns, D; Morgan, GJ; Houlston, RS; Houlston, RS; Kaiser, MF (2017-10)
      Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, ...
    • New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders 

      Matutes, E (2002-03)
      Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative ...
    • Nintedanib in ovarian cancer. 

      Khalique, S; Banerjee, S (2017-09)
      Advanced ovarian cancer remains an unmet clinical need. Angiogenesis is considered a therapeutic target in ovarian cancer, with bevacizumab, a monoclonal antibody against VEGF, being the first drug to show a progression-free ...
    • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. 

      Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2; Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; Aben, KK; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Antoniou, AC; Apicella, C; Arndt, V; Arnold, N; Arun, BK; Arver, B; Ashworth, A; Australian Ovarian Cancer Study Group; Baglietto, L; Balleine, R; Bandera, EV; Barrowdale, D; Bean, YT; Beckmann, L; Beckmann, MW; Benitez, J; Berger, A; Berger, R; Beuselinck, B; Bisogna, M; Bjorge, L; Blomqvist, C; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bolla, MK; Bonanni, B; Brand, JS; Brauch, H; Breast Cancer Family Register; Brenner, H; Brinton, L; Brooks-Wilson, A; Bruinsma, F; Brunet, J; Brüning, T; Budzilowska, A; Bunker, CH; Burwinkel, B; Butzow, R; Buys, SS; Caligo, MA; Campbell, I; Carter, J; Chang-Claude, J; Chanock, SJ; Claes, KBM; Collée, JM; Cook, LS; Couch, FJ; Cox, A; Cramer, D; Cross, SS; Cunningham, JM; Cybulski, C; Czene, K; Damiola, F; Dansonka-Mieszkowska, A; Darabi, H; de la Hoya, M; deFazio, A; Dennis, J; Devilee, P; Dicks, EM; Diez, O; Doherty, JA; Domchek, SM; Dorfling, CM; Dörk, T; Silva, IDS; du Bois, A; Dumont, M; Dunning, AM; Duran, M; Easton, DF; Eccles, D; Edwards, RP; Ehrencrona, H; Ejlertsen, B; Ekici, AB; Ellis, SD; EMBRACE; Engel, C; Eriksson, M; Fasching, PA; Feliubadalo, L; Figueroa, J; Flesch-Janys, D; Fletcher, O; Fontaine, A; Fortuzzi, S; Fostira, F; Fridley, BL; Friebel, T; Friedman, E; Friel, G; Frost, D; Garber, J; García-Closas, M; Gayther, SA; GEMO Study Collaborators; GENICA Network; Gentry-Maharaj, A; Gerdes, A-M; Giles, GG; Glasspool, R; Glendon, G; Godwin, AK; Goodman, MT; Gore, M; Greene, MH; Grip, M; Gronwald, J; Gschwantler Kaulich, D; Guénel, P; Guzman, SR; Haeberle, L; Haiman, CA; Hall, P; Halverson, SL; Hamann, U; Hansen, TVO; Harter, P; Hartikainen, JM; Healey, S; HEBON; Hein, A; Heitz, F; Henderson, BE; Herzog, J; T Hildebrandt, MA; Høgdall, CK; Høgdall, E; Hogervorst, FBL; Hopper, JL; Humphreys, K; Huzarski, T; Imyanitov, EN; Isaacs, C; Jakubowska, A; Janavicius, R; Jaworska, K; Jensen, A; Jensen, UB; Johnson, N; Jukkola-Vuorinen, A; Kabisch, M; Karlan, BY; Kataja, V; Kauff, N; KConFab Investigators; Kelemen, LE; Kerin, MJ; Kiemeney, LA; Kjaer, SK; Knight, JA; Knol-Bout, JP; Konstantopoulou, I; Kosma, V-M; Krakstad, C; Kristensen, V; Kuchenbaecker, KB; Kupryjanczyk, J; Laitman, Y; Lambrechts, D; Lambrechts, S; Larson, MC; Lasa, A; Laurent-Puig, P; Lazaro, C; Le, ND; Le Marchand, L; Leminen, A; Lester, J; Levine, DA; Li, J; Liang, D; Lindblom, A; Lindor, N; Lissowska, J; Long, J; Lu, KH; Lubinski, J; Lundvall, L; Lurie, G; Mai, PL; Mannermaa, A; Margolin, S; Mariette, F; Marme, F; Martens, JWM; Massuger, LFAG; Maugard, C; Mazoyer, S; McGuffog, L; McGuire, V; McLean, C; McNeish, I; Meindl, A; Menegaux, F; Menéndez, P; Menkiszak, J; Menon, U; Mensenkamp, AR; Miller, N; Milne, RL; Modugno, F; Montagna, M; Moysich, KB; Müller, H; Mulligan, AM; Muranen, TA; Narod, SA; Nathanson, KL; Ness, RB; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nielsen, SF; Nordestgaard, BG; Nussbaum, RL; Odunsi, K; Offit, K; Olah, E; Olopade, OI; Olson, JE; Olson, SH; Oosterwijk, JC; Orlow, I; Orr, N; Orsulic, S; Osorio, A; Ottini, L; Paul, J; Pearce, CL; Pedersen, IS; Peissel, B; Pejovic, T; Pelttari, LM; Perkins, J; Permuth-Wey, J; Peterlongo, P; Peto, J; Phelan, CM; Phillips, K-A; Piedmonte, M; Pike, MC; Platte, R; Plisiecka-Halasa, J; Poole, EM; Poppe, B; Pylkäs, K; Radice, P; Ramus, SJ; Rebbeck, TR; Reed, MWR; Rennert, G; Risch, HA; Robson, M; Rodriguez, GC; Romero, A; Rossing, MA; Rothstein, JH; Rudolph, A; Runnebaum, I; Salani, R; Salvesen, HB; Sawyer, EJ; Schildkraut, JM; Schmidt, MK; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schrauder, MG; Schumacher, F; Schwaab, I; Scuvera, G; Sellers, TA; Severi, G; Seynaeve, CM; Shah, M; Shrubsole, M; Siddiqui, N; Sieh, W; Simard, J; Singer, CF; Sinilnikova, OM; Smeets, D; Sohn, C; Soller, M; Song, H; Soucy, P; Southey, MC; Stegmaier, C; Stoppa-Lyonnet, D; Sucheston, L; SWE-BRCA; Swerdlow, A; Tangen, IL; Tea, M-K; Teixeira, MR; Terry, KL; Terry, MB; Thomassen, M; Thompson, PJ; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Tsimiklis, H; Tung, N; Tworoger, SS; Tyrer, JP; Vachon, CM; Van 't Veer, LJ; van Altena, AM; Van Asperen, CJ; van den Berg, D; van den Ouweland, AMW; van Doorn, HC; Van Nieuwenhuysen, E; van Rensburg, EJ; Vergote, I; Verhoef, S; Vierkant, RA; Vijai, J; Vitonis, AF; von Wachenfeldt, A; Walsh, C; Wang, Q; Wang-Gohrke, S; Wappenschmidt, B; Weischer, M; Weitzel, JN; Weltens, C; Wentzensen, N; Whittemore, AS; Wilkens, LR; Winqvist, R; Wu, AH; Wu, X; Yang, HP; Zaffaroni, D; Pilar Zamora, M; Zheng, W; Ziogas, A; Chenevix-Trench, G; Pharoah, PDP; Rookus, MA; Hooning, MJ; Goode, EL (2016-05)
      OBJECTIVE:Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer ...
    • NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL 

      Larrayoz, M; Rose-Zerilli, MJ; Parker, H; Blakemore, SJ; Forster, J; Davis, Z; Steele, AJ; Else, M; Catovsky, D; Oscier, DG; Strefford, JC (2016-06)
    • Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. 

      Hahne, JC; Valeri, N (2018-01)
      Non-coding RNAs are important regulators of gene expression and transcription. It is well established that impaired non-coding RNA expression especially the one of long non-coding RNAs and microRNAs is involved in a number ...
    • The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progression. 

      Liu, NQ; Ter Huurne, M; Nguyen, LN; Peng, T; Wang, S-Y; Studd, JB; Joshi, O; Ongen, H; Bramsen, JB; Yan, J; Andersen, CL; Taipale, J; Dermitzakis, ET; Houlston, RS; Hubner, NC; Stunnenberg, HG (2017-02-14)
      Genome-wide association studies have identified a great number of non-coding risk variants for colorectal cancer (CRC). To date, the majority of these variants have not been functionally studied. Identification of ...
    • Non-Invasive Prostate Cancer Characterization with Diffusion-Weighted MRI: Insight from In silico Studies of a Transgenic Mouse Model. 

      Hill, DK; Heindl, A; Zormpas-Petridis, K; Collins, DJ; Euceda, LR; Rodrigues, DN; Moestue, SA; Jamin, Y; Koh, D-M; Yuan, Y; Bathen, TF; Leach, MO; Blackledge, MD (2017-01)
      Diffusion-weighted magnetic resonance imaging (DWI) enables non-invasive, quantitative staging of prostate cancer via measurement of the apparent diffusion coefficient (ADC) of water within tissues. In cancer, more advanced ...
    • Noninvasive detection of carboxypeptidase G2 activity in vivo. 

      Jamin, Y; Smyth, L; Robinson, SP; Poon, ESC; Eykyn, TR; Springer, CJ; Leach, MO; Payne, GS (2011-05)
      The pseudomonad protein, carboxypeptidase G2 (CPG2), is a prodrug-activating enzyme utilized in the targeted chemotherapy strategies of antibody- and gene-directed enzyme prodrug therapy (ADEPT and GDEPT). We have developed ...
    • Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 

      Gevensleben, H; Garcia-Murillas, I; Graeser, MK; Schiavon, G; Osin, P; Parton, M; Smith, IE; Ashworth, A; Turner, NC (2013-06)
      PURPOSE:Digital PCR is a highly accurate method of determining DNA concentration. We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and ...
    • Nothing in cancer makes sense except…. 

      Greaves, M (2018-02-21)
      Paraphrasing Dobzhansky's famous dictum, I discuss how interrogating cancer through the lens of evolution has transformed our understanding of its development, causality and treatment resistance. The emerging picture of ...
    • Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer 

      Buus, R; Yeo, B; Brentnall, A; Klintman, M; Cheang, M; Khabra, K; Sestak, I; Gao, Q; Cuzick, J; Dowsett, M
    • Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. 

      Buus, R; Yeo, B; Brentnall, AR; Klintman, M; Cheang, MCU; Khabra, K; Sestak, I; Gao, Q; Cuzick, J; Dowsett, M (2018-09-04)
      BACKGROUND:Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ...
    • Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias 

      Matutes, E (2012-06)
      Rarer chronic lymphoid leukaemias represent a challenge to the clinicians due to the limited information on their pathogenesis, difficulties on setting up prospective clinical trials and to their refractoriness to drugs ...
    • A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors 

      Carter, Paul (2016-11)
      Clinically aggressive disease behavior is difficult to predict in men with low to intermediate clinical risk prostate cancer and methylation biomarkers may be a valuable adjunct for assessing the management of these patients. ...